Funding for Relievant Medsystems’ Intracept Procedure

Relievant Medsystems Intracept Procedure

Relievant Medsystems completed the close of its $50 million Series G financing. Funds will support commercialization efforts for the Intracept procedure to treat vertebrogenic pain.

Relievant Medsystems’ minimally invasive Intracept procedure is reported to be the only FDA-cleared treatment for chronic vertebrogenic low back pain, using...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us